Join Growin Stock Community!

Pmv pharmaceuticals, inc.PMVP.US Overview

US StockHealthcare
(No presentation for PMVP)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

PMVP AI Insights

PMVP Overall Performance

PMVP AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PMVP Recent Performance

7.94%

Pmv pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

PMVP PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

PMVP Key Information

PMVP Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

PMVP Profile

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

Price of PMVP

PMVP FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PMVP Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.55
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.75
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.55
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.75
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is PMVP's latest earnings report released?

    The most recent financial report for Pmv pharmaceuticals, inc. (PMVP) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PMVP's short-term business performance and financial health. For the latest updates on PMVP's earnings releases, visit this page regularly.

  • How much debt does PMVP have?

    As of the end of the reporting period, Pmv pharmaceuticals, inc. (PMVP) had total debt of 931K, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does PMVP have?

    At the end of the period, Pmv pharmaceuticals, inc. (PMVP) held Total Cash and Cash Equivalents of 36.34M, accounting for 0.27 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is PMVP's EPS continuing to grow?

    According to the past four quarterly reports, Pmv pharmaceuticals, inc. (PMVP)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.4. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of PMVP?

    Pmv pharmaceuticals, inc. (PMVP)'s Free Cash Flow (FCF) for the period is -19.82M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 17.89% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.